New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options
Penumbra announced new data showing that patients with intermediate-risk pulmonary embolism (PE) treated with their computer assisted vacuum thrombectomy (CAVT) technology experienced better outcomes compared to other treatments. The study, presented at VIVA 2024, analyzed 2,060 adult patients and revealed that CAVT resulted in 25-35% shorter hospital stays, 25-30% higher rates of home discharge, and 2-3 times fewer complications. The technology also demonstrated potential financial benefits, with hospitals potentially seeing up to a 75% gain in profitable contribution margin if 10% more patients are treated with CAVT compared to anticoagulation alone.
Penumbra ha annunciato nuovi dati che mostrano che i pazienti con embolia polmonare a rischio intermedio (PE) trattati con la loro tecnologia di trombectomia a vuoto assistita da computer (CAVT) hanno avuto risultati migliori rispetto ad altri trattamenti. Lo studio, presentato al VIVA 2024, ha analizzato 2.060 pazienti adulti e ha rivelato che la CAVT ha portato a degenze ospedaliere più brevi del 25-35%, tassi di dimissione a domicilio superiori del 25-30% e 2-3 volte meno complicazioni. La tecnologia ha anche dimostrato potenziali benefici finanziari, con gli ospedali che potrebbero vedere fino a un guadagno del 75% nel margine di contribuzione redditizia se il 10% in più di pazienti viene trattato con CAVT rispetto all'uso esclusivo di anticoagulanti.
Penumbra anunció nuevos datos que muestran que los pacientes con embolia pulmonar de riesgo intermedio (PE) tratados con su tecnología de trombectomía por vacío asistida por computadora (CAVT) experimentaron mejores resultados en comparación con otros tratamientos. El estudio, presentado en VIVA 2024, analizó a 2,060 pacientes adultos y reveló que la CAVT resultó en estancias hospitalarias de 25-35% más cortas, tasas de alta a domicilio de 25-30% más altas, y de 2 a 3 veces menos complicaciones. La tecnología también demostró potenciales beneficios financieros, con los hospitales que podrían ver hasta un 75% de ganancia en el margen de contribución rentable si se trata a un 10% más de pacientes con CAVT en comparación con la anticoagulación únicamente.
펜움브라(Penumbra)는 중간 위험 폐색전증(PE) 환자들이 컴퓨터 보조 진공 혈전제거술(CAVT) 기술로 치료받을 때 다른 치료법에 비해 더 좋은 결과를 보였다는 새로운 데이터를 발표했습니다. VIVA 2024에서 발표된 이 연구는 2,060명의 성인 환자를 분석하였으며, CAVT를 통해 병원에서의 평균 입원 기간이 25-35% 단축되고, 퇴원 후 자택으로 돌아가는 비율이 25-30% 증가하며, 합병증이 2-3배 적다는 결과를 보여주었습니다. 이 기술은 또한 재정적 이점의 가능성을 보여주었으며, CAVT로 치료받는 환자가 10% 더 많을 경우 병원은 수익 기여 마진이 75% 증가할 수 있습니다.
Penumbra a annoncé de nouvelles données montrant que les patients présentant une embolie pulmonaire à risque intermédiaire (EP), traités avec leur technologie de thrombectomie par aspiration assistée par ordinateur (CAVT), ont connu de meilleurs résultats par rapport à d'autres traitements. L'étude, présentée à VIVA 2024, a analysé 2 060 patients adultes et a révélé que la CAVT a permis des séjours à l'hôpital 25-35% plus courts, des taux de sortie à domicile 25-30% plus élevés et 2-3 fois moins de complications. La technologie a également montré des avantages financiers potentiels, les hôpitaux pouvant voir jusqu'à un bénéfice de 75% dans la marge de contribution rentable si 10% de patients supplémentaires sont traités avec CAVT par rapport à l'anticoagulation seule.
Penumbra gab neue Daten bekannt, die zeigen, dass Patienten mit intermediärem Risiko für eine Lungenembolie (PE), die mit ihrer computerassistierten Vakuumthrombektomie-Technologie (CAVT) behandelt wurden, bessere Ergebnisse im Vergleich zu anderen Behandlungen erzielten. Die Studie, die auf der VIVA 2024 präsentiert wurde, analysierte 2.060 Erwachsene und zeigte, dass CAVT zu 25-35% kürzeren Krankenhausaufenthalten, 25-30% höheren Entlassungsraten nach Hause und 2-3-mal weniger Komplikationen führte. Die Technologie zeigte auch potenzielle finanzielle Vorteile, wobei Krankenhäuser möglicherweise bis zu einen 75% Gewinn im profitablen Beitragsmargen sehen könnten, wenn 10% mehr Patienten mit CAVT im Vergleich zur alleinigen Antikoagulation behandelt werden.
- 25-35% reduction in hospital length of stay
- 25-30% higher rate of patients discharged home
- 2-3 times fewer complications compared to other treatments
- 75% potential gain in profitable contribution margin for hospitals
- Comparable in-hospital mortality rates to other treatment options
- None.
Insights
The clinical data from this large-scale study (n=2,060) demonstrates significant advantages for Penumbra's CAVT technology in treating pulmonary embolism. Key findings show
The propensity score matched analysis provides robust evidence for CAVT's clinical superiority. The Lightning Flash portfolio's dual clot detection algorithms and MaxID hypotube technology represent meaningful technological advantages over existing solutions. This data strongly positions Penumbra to capture greater market share in the thrombectomy space, particularly given the significant health economic benefits demonstrated.
This study presents compelling economic advantages that should drive hospital adoption of Penumbra's CAVT technology. The demonstrated reduction in hospital stays and complications directly translates to cost savings for healthcare systems. The projected
These findings should accelerate the conversion of hospitals to CAVT technology, potentially expanding Penumbra's market penetration and revenue growth. The combination of superior clinical outcomes and clear economic benefits creates a strong value proposition that could drive sustained growth in the thrombectomy segment.
- Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference
- Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system
"This first-of-a-kind analysis demonstrates that patients treated with CAVT utilized fewer hospital resources," said Parag J. Patel, M.D., M.S., FSIR, who presented the data and is an interventional radiologist at Froedtert Hospital in
The retrospective study utilized the Vizient Clinical Data Base to identify 2,060 adult (³18 years) inpatients with intermediate-risk PE. This rigorous 1:1 propensity score matched analysis included resource use and health outcomes among patients in the
When compared to other modalities studied, the data showed that CAVT resulted in:
- 25-35 percent shorter total hospital length of stay
- 25-30 percent higher average rate of patients discharged home
- 2-3 times fewer average composite complications
"CAVT will continue to redefine the way physicians treat symptomatic PE. We have a growing body of evidence that demonstrates the meaningful benefits of CAVT on patient outcomes," said James F. Benenati, M.D., FSIR, chief medical officer at Penumbra. "Now with this study, the findings suggest that by increasing patient access to advanced therapies like CAVT, it can also have an important, positive impact on hospital systems by greatly reducing resource utilization versus other modalities, therefore decreasing the overall cost to the healthcare system."
In the study, CAVT was associated with improvement in contribution margin relative to anticoagulation alone. An example given was that if 10 percent more patients are treated with CAVT, hospitals could see up to a 75 percent gain in profitable contribution margin, representing thousands of dollars more per patient compared to treatment with anticoagulation alone. This data was presented separately in a symposium during the VIVA 2024 Conference.
Penumbra's Lightning Flash portfolio is the most advanced mechanical thrombectomy system on the market to address venous and pulmonary thrombus. It features Penumbra's Lightning CAVT technology with the latest dual clot detection algorithms, using both pressure and flow-based processes to detect blood clot and blood flow. The Lightning Flash™ and Lightning Flash™ 2.0 catheters are made with MaxID hypotube technology, allowing an inner diameter similar to large-bore catheters while maintaining a lower profile and a soft, atraumatic tip design. They are designed to help remove blood clots with speed, safety and simplicity, allowing physicians to better navigate the body's complex anatomy and deliver high power aspiration for clot removal.
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.
Important Safety Information
Additional information about Penumbra's products can be located on Penumbra's website at https://www.penumbrainc.com/providers. Prior to use, please refer to Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events and detailed instructions for use. Risk information can be found at http://www.peninc.info/risk.
Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 22, 2024. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Contact | ||
Jennifer Heth | Parinaz Farzin | |
Penumbra, Inc. | Merryman Communications | |
510-995-9791 | 310.600.6746 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-late-breaking-data-show-patients-treated-with-penumbras-computer-assisted-vacuum-thrombectomy-technology-for-pulmonary-embolism-experience-shorter-hospital-stays-and-fewer-complications-compared-to-other-treatment-options-302296321.html
SOURCE Penumbra, Inc.
FAQ
What are the key benefits of Penumbra's CAVT technology for PE treatment?
How does Penumbra's CAVT technology impact hospital finances?
What were the main findings of the CAVT study presented at VIVA 2024?
